The Munich MedtechStartup Reactive Robotics aims to become the pacesetter in AI and robot-assisted mobilization in hospitals, geriatrics, and care. Investors such as Dr. Doll, TQ-Group, Henrik Schunk, Stephan Huber, and the EIC Fund share the vision and are providing Reactive Robotics with five million euros for its continued growth. In 2023, the company already received €2.5 million in funding for its R&D activities from European Innovation Council approved.
Reactive Robotics: Driving market launch nationally and internationally
With the new financing, the Munich-based startup intends to further develop its AI-supported robotic assistance system Vemotion for patients and caregivers, therapists and physicians and to continue its targeted market launch nationally and internationally.
With its assistive robotics, critically ill and intensive care patients can be mobilized early, which is crucial for faster recovery. It is also intended to relieve the physical strain on nursing and therapy staff when working with patients weighing up to 180 kg, and with its "colleague Vemotion," it will create new freedom despite staff shortages.
Brigitte Schrätzenstaller, Managing Director of Reactive Robotics, is pleased with the current investment:
"We are thrilled by the trust our investors have placed in us. This financing round is a significant step for Reactive Robotics and enables us to realize our vision of improved and efficient patient care and reducing staff burdens."
“Promising player in the field of medical robotics”
Maximilian Große-Dunker, Managing Director and COO, emphasizes:
“With additional resources, we will consistently pursue our data strategy and internationalization.”
And investor Dr. Theo Doll added:
"We firmly believe in Reactive Robotics's potential to revolutionize the healthcare industry. The combination of innovative technology and the dedicated team makes the company a promising player in the field of medical robotics."
